



18 January 2024

Our Ref: RFI 55658

Dear

**Freedom of Information Act 2000
Information in Relation to the Number of Patients treated by the
Rheumatology Department**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 6 January 2024.

A response to each of the questions raised has been provided by the Surgery & Elective, Maternity & Paediatric Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs listed in Table 1.

A1. Please see Table 1 for the time period 01/08/2023 to 31/10/2023.

Table 1

Treatment	No. of Patients Treated
Abatacept [Orencia]	39
Adalimumab [Humira]	64
Adalimumab Biosimilars	377
Apremilast [Otezla]	2
Baricitinib [Olumiant]	26
Bimekizumab [Bimzelx]	Nil
Certolizumab [Cimzia]	20
Etanercept [Enbrel]	38
Etanercept Biosimilars	161
Filgotinib [Jyseleca]	Nil
Golimumab [Simponi]	83
Guselkumab [Tremfya]	2
Infliximab [Remicade]	4
Infliximab Biosimilars	9
Ixekizumab [Taltz]	20
Risankizumab [Skyrizi]	Nil
Rituximab [MabThera]	1
Rituximab Biosimilars	19
Sarilumab [Kevzara]	3
Secukinumab [Cosentyx]	69
Tocilizumab [Ro Actemra]	72
Tocilizumab Biosimilars	Nil
Tofacitinib [Xeljanz]	2
Upadacitinib [Rinvoq]	8
Ustekinumab [Stelara]	4

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.

- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Golimumab [Simponi]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Secukinumab [Cosentyx]**
- **Tofacitinib [Xeljanz]**
- **Upadacitinib [Rinvoq]**

A2. The Trust is unable to provide the level of detail requested due to the lack of electronic prescribing system.